‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide